|Bid||0.5805 x 800|
|Ask||0.5816 x 3000|
|Day's Range||0.5750 - 0.5890|
|52 Week Range||0.3600 - 1.1300|
|Beta (5Y Monthly)||1.55|
|PE Ratio (TTM)||3.85|
|Earnings Date||May 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.17|
Genesis tops the list Continue reading...
Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced reinitiation of enrollment of its Phase 2 study with PL9643 for the treatment of dry eye disease (DED).
Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) announced that its 2020 Annual Meeting of Stockholders that convened on June 25, 2020 has been adjourned until July 23, 2020 at 9:00 a.m. Eastern Daylight Time to solicit additional proxies for Proposal 4, approval of an amendment to our Certificate of Incorporation to effect an increase in authorized common stock from 300,000,000 shares to 500,000,000 shares. The adjourned meeting will be a completely "virtual" meeting of stockholders, and stockholders will be able to listen and participate in the virtual annual meeting as well as vote and submit your questions during the live webcast of the meeting by visiting http://www.virtualshareholdermeeting.com/PTN2020 and entering the 16–digit control number included in your Notice Regarding the Availability of Proxy Materials, on your proxy card or in the instructions that accompanied your proxy materials.